DARZALEX FASPRO® dosing schedules for adult patients with newly diagnosed multiple myeloma*

For adults patients who are newly diagnosed and are transplant ineligible, DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with lenalidomide and dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone. DARZALEX FASPRO® is a ready-to-use, single-use vial, which includes a fixed dose and no weight-based calculations.1,2

Dosing frequency decreases over time1
DARZALEX FASPRO® with the DRd regimen
Continue DARZALEX FASPRO® + Rd until disease progression or unacceptable toxicity1
Administer medications before and after administration of DARZALEX FASPRO® to minimize systemic ARRs.1

First dose of the every-2-week dosing schedule is given at Week 9.

First dose of the every-4-week dosing schedule is given at Week 25.

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.

ARRs=administration-related reactions; DRd=DARZALEX FASPRO® (D) + lenalidomide (R) + dexamethasone (d).